MJB ADHD · Static reading view · Interactive version
Status: drafted · Content checked 2026-10-06
Claim-level corrections to this campaign's own October 2026 documents — the legal briefing, the observation journal and the continuity report. Originals are preserved; this overlay governs reuse.
An accountability campaign is only as strong as its accuracy. An independent review of three documents produced on 6 October 2026 found places where the wording went further than the evidence. They are corrected here rather than quietly edited, so anyone can see what changed and why.
Documents covered: Reinstatement & Accountability Legal Briefing v1 AUTHOR-ACCOUNT; Medication Observation Journal v2 AUTHOR-ACCOUNT; When Treatment Stops v2.
| # | Original claim | Problem | Use instead |
|---|---|---|---|
| C1 | Briefing N6 treats COM/46 as current policy | Project records state it was replaced by an all-age policy from 14 May 2026 P3 | "While COM/46 was in force (to 14 May 2026)…"; obtain the replacement policy for later events |
| C2 | "CWPT discharged him on 31 December 2025 with no taper, bridge or receiving prescriber" | The trust's 5 March letter records a patient-requested discharge on 11 December after a review was offered; the patient disputes the context AUTHOR-ACCOUNT | Show both accounts; separate last supply, last dose, discharge request, closure and discharge letter |
| C3 | "279 days without treatment" as a fact | Correct arithmetic only for an assumed start date | State the start date used and the as-of date; no live counter |
| C4 | "The only stated clinical barrier expired" | The letter says medication "cannot be considered until" full cardiology checks — a prerequisite, not a promise AUTHOR-ACCOUNT | "After the reported heart-check result, what remained outstanding and who owned it?" |
| C5 | "Interruption returns a person to a higher-risk state" (registry data) | Those studies compare starting with not starting; they do not measure withdrawal W2W3 | "These findings support concern about unmet need; they do not establish the size of interruption-related harm" |
| C6 | Amfexa is "the licensed ADHD product" | Its ADHD licence is for ages 6–17 after inadequate methylphenidate response; adult use is off-label W4 | "Off-label in adults, a specialist decision"; another ICB's agreement is not a local rule P1 |
| C7 | "Restarting Elvanse adds no cardiac safety over Amfexa" | A shared active drug does not prove equal safety; exposure profiles differ R10 | Remove; ask what current assessment shows |
| C8 | "A gap does not erase tolerance" (patient addendum) | Unsupported as a clinical fact AUTHOR-ACCOUNT | Accept cautious re-titration; dispute the product choice, not the pace |
| C9 | "80% gait restoration" | A patient report recorded by a clinician, not a measurement AUTHOR-ACCOUNT | "Patient-reported, recorded by…" |
| C10 | REQoL-20 score quoted as a validated result | Instrument and scoring not yet inspected AUTHOR-ACCOUNT | Hold until the completed form is attached |
| C11 | Amfexa "isomalt only" | False: 10 mg also has magnesium stearate and iron oxide; 5 mg has crospovidone W4 | Use the full ingredient list per strength |
| C12 | "Four fills in four years is the opposite of drug-seeking" | Non-collection does not rule out misuse; safe prescribing needs individual assessment AUTHOR-ACCOUNT | "Dispensing records can clarify exposure"; present the 2025 episode and the plan that followed together |
| C13 | Items marked "verified" in the briefing | Verified by an assistant reading the mailbox or project files, not by an independent reviewer with the primary exhibit AUTHOR-ACCOUNT | Label as "pointer — exhibit pending" until attached |
| C14 | Journal says the 5 March letter mentioned guanfacine | The supplied 5 March letter does not AUTHOR-ACCOUNT | Remove or locate the source of the guanfacine statement |
| C15 | Safeguarding definition presented as establishing a duty | A definition anchors a question; statutory duties need further conditions P2 | "Raises the question whether…" |
| C16 | Duty-of-candour and legal deadlines stated generally | Need individual legal application and verified dates | Leave to the solicitor; mark "arguable" |
| C17 | "Their best defence / why it fails" framing | Presents an incomplete record as a settled verdict | Reframe as "possible explanation / evidence needed / remaining question" |
| C18 | Elvanse top dose given as 280 mg in places | Trust records say 140 mg then 210 mg AUTHOR-ACCOUNT | Use 210 mg, sourced to the trust record |
Most corrections narrow a claim rather than reverse it. Two change the story materially: C2, because the discharge is genuinely disputed; and C5, because the strongest population studies are about starting treatment, not stopping it. The strongest direct evidence on stopping in adults is a short randomised withdrawal trial showing rapid symptom relapse R1.
Several corrections depend on records not yet obtained; once they arrive, some may change again.